Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1483 • 2019 ACR/ARP Annual Meeting
Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study
Lyn Ferguson¹, Paul Welsh ¹, Rosemary Brown ¹, Alistair Tindell ², Sean Kerrigan ³, Naveed Sattar ¹, Iain McInnes ⁴ and Stefan Siebert ⁴, ¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, Glasgow, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is associated with obesity and increased cardiometabolic risk. Weight loss has been noted in association with the phosphodiesterase 4 (PDE4) inhibitor…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai¹, Rebecca Manno ², Jamie Perin ³, Noori Kim ⁴, Katherine C. Smith ⁵, Albert W Wu ⁶, Clifton Bingham ⁷ and Uzma Haque ², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Johns Hopkins University School of Public Health, Department of International Health, Baltimore, ⁴Johns Hopkins University School of Medicine, Department of Dermatology, Baltimore, MD, ⁵Johns Hopkins University Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, ⁶Johns Hopkins University Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…
Abstract Number: 2475 • 2019 ACR/ARP Annual Meeting
Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Peter Hur ², Mei Liu ³, Sabrina Rebello ³, Robert McLean ³, Blessing Dube ³, Meghan Glynn ⁴ and Philip Mease ⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease of the skin and musculoskeletal system. Six key domains of PsA have been identified to…
Abstract Number: 2498 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study
Sahil Koppikar¹, Keith Colaco ², Paula Harvey ³, Vinod Chandran ⁴, Dafna Gladman ⁵, Richard Cook ⁶ and Lihi Eder ⁷, ¹University of Toronto, Markham, ON, Canada, ²University of Toronto, Women's College Hospital, University Health Network, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada, ⁷Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: Data about heart failure (HF) in patients with psoriatic disease (PsD) are sparse. The aims of the study were to: 1) determine the incidence…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…
Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting
Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.
Viviana Marzaioli¹, Mary Canavan¹, Achilleas Floudas¹, Siobhan C. Wade¹, Candice Low², Douglas J. Veale² and Ursula Fearon¹, ¹Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland
Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
Abstract Number: 2594 • 2018 ACR/ARHP Annual Meeting
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Kurt de Vlam¹, Alexis Ogdie², Andrew G Bushmakin³, Joseph C Cappelleri³, Roy Fleischmann⁴, Peter C. Taylor⁵, Valderilio F Azevedo⁶, Lara Fallon⁷, Anna Maniccia⁸, John Woolcott⁹ and Philip J. Mease¹⁰, ¹UZ Leuven, Leuven, Belgium, ²University of Pennsylvania, Philadelphia, PA, ³Pfizer Inc, Groton, CT, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵University of Oxford, Oxford, United Kingdom, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Pfizer Canada, Montreal, QC, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA, ¹⁰Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…
Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting
High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment
Konstantinos Thomas¹, Anastasia Makris¹, Christina Tsalapaki¹, Argyro Lazarini¹, Kalliopi Klavdianou¹, Katerina Antonatou¹, Christos Koutsianas¹, Chrisoula Hatzara¹, Emilia Hadziyannis¹ and Dimitrios Vassilopoulos², ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
Abstract Number: 2595 • 2018 ACR/ARHP Annual Meeting
Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Valeria Biermann⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Lehrstuhl für Gesundheitsmanagement, Universität Erlangen-Nürnberg, Nürnberg, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various clinical trials. Data from socio- and health economic parameters and costs in daily clinical…
Abstract Number: 1517 • 2018 ACR/ARHP Annual Meeting
Integrated Safety Analysis across Phase 3 Clinical Studies Including the Controlled and Uncontrolled Periods for Intravenous Golimumab in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Arthur Kavanaugh¹, Atul A. Deodhar², Sergio Schwartzman³, Shelly Kafka⁴, Soumya D Chakravarty⁵, Elizabeth C Hsia⁶, Diane D. Harrison⁷, Jocelyn Leu⁷, Yiying Zhou⁷, Kim Hung Lo⁷ and M. Elaine Husni⁸, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Oregon Health & Science U, Portland, OR, ³Weill Cornell Medical College, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA, ⁶Janssen Reseach & Development, LLC/ U of Pennsylvania School of Medicine, Spring House/Philadelphia, PA, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: The GO-FURTHER, GO-VIBRANT, and GO-ALIVE randomized controlled trials evaluated the efficacy and safety of intravenous (IV) golimumab (GLM) in patients (pts) with active rheumatoid…
Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Madeline J. Epsten¹, Lisa A. Mandl¹, Jackie Szymonifka² and Sergio Schwartzman¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…
Abstract Number: 1591 • 2018 ACR/ARHP Annual Meeting
Is Enthesitis a Marker of Disease Severity in Early Psoriatic Arthritis?
Lihi Eder¹, Chandra Farrer² and Dana Jerome³, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Rheumatology, Women's College Hospital, Toronto, ON, Canada, ³University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a key feature in psoriatic arthritis (PsA) affecting approximately a third of the patients. Ultrasound improves the detection of enthesitis compared to…
Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Thomas Renson³, Roos Colman⁴, Dirk Elewaut⁵ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ⁴Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, ⁵Ghent University Hospital and VIB Ghent University, Ghent, Belgium, ⁶Rheumatology, Ghent University Hospital and VIB Ghent University, Gent, Belgium
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].